A223250 Stock Overview
DreamCIS, Inc. provides clinical research services in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
DreamCIS, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,965.00 |
| 52 Week High | ₩9,750.00 |
| 52 Week Low | ₩2,610.00 |
| Beta | 0.28 |
| 1 Month Change | -1.82% |
| 3 Month Change | -4.97% |
| 1 Year Change | 5.70% |
| 3 Year Change | -32.23% |
| 5 Year Change | n/a |
| Change since IPO | -61.11% |
Recent News & Updates
Shareholder Returns
| A223250 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 11.0% | -0.5% | -0.4% |
| 1Y | 5.7% | 2.2% | 4.5% |
Return vs Industry: A223250 exceeded the KR Life Sciences industry which returned 2.2% over the past year.
Return vs Market: A223250 exceeded the KR Market which returned 4.5% over the past year.
Price Volatility
| A223250 volatility | |
|---|---|
| A223250 Average Weekly Movement | 4.5% |
| Life Sciences Industry Average Movement | 7.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A223250 has not had significant price volatility in the past 3 months.
Volatility Over Time: A223250's weekly volatility has decreased from 12% to 4% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 272 | n/a | www.dreamcis.com |
DreamCIS, Inc. provides clinical research services in South Korea. It offers clinical development services; biostatic, data and project management, pharmacovigilance, medical writing, site start up, clinical monitoring, Dreamtrial, IWRS, and quality assurance services; medical device development services; and regulatory consulting services. The company was founded in 2000 and is headquartered in Seoul, South Korea.
DreamCIS, Inc. Fundamentals Summary
| A223250 fundamental statistics | |
|---|---|
| Market cap | ₩68.36b |
| Earnings (TTM) | ₩3.74b |
| Revenue (TTM) | ₩47.84b |
18.3x
P/E Ratio1.4x
P/S RatioIs A223250 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A223250 income statement (TTM) | |
|---|---|
| Revenue | ₩47.84b |
| Cost of Revenue | ₩34.91b |
| Gross Profit | ₩12.94b |
| Other Expenses | ₩9.20b |
| Earnings | ₩3.74b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 162.18 |
| Gross Margin | 27.04% |
| Net Profit Margin | 7.81% |
| Debt/Equity Ratio | 1.4% |
How did A223250 perform over the long term?
See historical performance and comparison